Immunomedics' cancer drug helps reduce tumor size in early-stage study

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Updates with details on Trodelvy, background

Sept 18 (Reuters) - Immunomedics, Inc IMMU.O said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Last week, to gain access to Trodelvy, Gilead Sciences Inc GILD.O said it will acquire Immunomedics in a $21 billion deal. The drug was granted an accelerated FDA approval in April for breast cancer treatment.

Trodelvy is a so-called antibody-drug conjugates, or ADC, that zero in on tumors to release cytotoxins that deliver up to 10,000 times the potency of standard chemotherapy, while minimizing damage to healthy tissues.

National Cancer Institute estimates about 24,000 Americans would be diagnosed with brain cancer and about 18,000 people will die from the disease in the United States in 2020.

(Reporting by Manas Mishra and Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More